An observational study in Glaucoma, sponsored by Association for Innovation and Biomedical Research on Light and Image. Not yet recruiting at 10 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Association for Innovation and Biomedical Research on Light and Image · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Glaucoma with a site in United Kingdom — 4 open to participants now, 5 under way, none of them phase 3. Glaucoma · United Kingdom.
Among the 48 studies in Glaucoma with a site in United Kingdom, this one has the largest planned enrollment of the 20 observational ones that give a count, is one of 2 that started in 2026, is one of 20 observational ones, and was the 47th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →4 of the 48 studies in Glaucoma with a site in United Kingdom are open now. Recruiting first, the newest first:
Buckinghamshire Healthcare NHS Trust · Sites in United Kingdom
Ages 18–99
iSTAR Medical · Sites in United Kingdom, Honduras
Ages 20+
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 18–110
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 7 · Phase 4 6
First in 1999; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 101 across 386 observational studies indexed under Glaucoma.
Median enrollment 90 across the 28 interventional studies, 100 across the 20 observational. Of the 37 that completed or were terminated, 14 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 48 have an industry lead sponsor. The 10 most frequent:
Association for Innovation and Biomedical Research on Light and Image is the lead sponsor of 38 studies on the registry; 5 are open to participants now.
Association for Innovation and Biomedical Research on Light and Image has 3 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Glaucoma with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07009236iSTAR MedicalA Study Evaluating the Safety and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma | 2026-12 |
| NCT05024695iSTAR MedicalEvaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies in Glaucoma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate whether prostaglandin analogue eye drops have a direct neuroprotective effect on retinal ganglion cells - beyond their intraocular pressure (IOP)-lowering effect - in adult patients with glaucoma or ocular hypertension. The study includes individuals diagnosed with glaucoma (any sex/gender, adult age groups) undergoing standard clinical treatment. The main questions it aims to answer are:
Researchers will compare an interventional group, which consist of 750 eyes treated with prostaglandin analogues (e.g., latanoprost, travoprost, tafluprost, bimatoprost, unoprostone), with a control group, which consist of 750 eyes treated with non-prostaglandin IOP-lowering compounds (e.g., timolol, dorzolamide, brimonidine, netarsudil) to see if treatment with prostaglandin analogues is associated with better retinal ganglion cell survival over a period of 3 years (36 months).
Data will be collected from individuals who had at least 36 months of documented follow-up, with clinical data available at approximately 3, 6, 12, 24, and 36 months. Eligible individuals must have been treated with either prostaglandin analogues or other intraocular pressure (IOP)-lowering agents as part of routine clinical care. The data to be obtained from medical records will include at least:
Glaucoma is among the most prevalent causes of irreversible blindness and is characterized by a progressive, irreversible degeneration of the retinal ganglion cells. Elevated intraocular pressure (IOP) is the most important glaucoma risk factor and the only risk factor that is readily modifiable with established treatment options, which include pharmacological approaches, laser treatment, and surgery. However, in many patients the disease progresses even after IOP is effectively lowered. Hence, neuroprotective treatment approaches that go beyond IOP lowering are needed.
Prostaglandin analogue eye drops reduce IOP by increasing uveoscleral outflow and are a well-established treatment option in ocular hypertension and glaucoma. Animal studies suggest that prostaglandin analogues may have a direct neuroprotective effect on retinal ganglion cells in addition to the effect mediated by IOP lowering. Proposed mechanisms of action include inhibiting of caspase-3 and cyclooxygenase as well as activation of polypeptide 2B1 and Klotho protein. However, this proposed additional, direct neuroprotective effect has not yet been tested in human patients. The viability and functional status of the retinal ganglion cells in glaucoma can be assessed by morphological readings, the standard nowadays being various optical coherence tomography modalities, and by visual field testing. Detection of Apoptosing Retinal Cells (DARC) is another, relatively novel technology that allows for quantification of retinal ganglion cell death, presumably on a much shorter time scale.
This is an observational, retrospective and longitudinal clinical study, according to the normal clinical practice.
This study aims to evaluate prostaglandin analogues neuroprotective effect on retinal ganglion cells apart from intraocular pressure (IOP)-lowering over a period of 3 years (36 months) and whether treatment of ocular hypertension and glaucoma participants with prostaglandin analogues should be promoted/ favoured over other IOP-lowering compounds. It will have a follow-up at 3, 6, 12, 24, and 36 months in eyes with glaucoma treated with prostaglandin analogues or a different topically applied compound.
1500 eyes (750 treated with prostaglandin analogues and 750 treated with a different IOP-lowering compound)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
750 eyes treated with intraocular pressure-lowering compounds that do not belong to the prostaglandin analogue class. These treatments may include beta-adrenergic blocking agents (e.g., timolol, betaxolol), carbonic anhydrase inhibitors (e.g., dorzolamide, brinzolamide), alpha-2 adrenergic agonists (e.g., brimonidine) or rho kinase inhibitors (e.g., netarsudil).
750 eyes treated with any prostaglandin analogue, such as latanoprost (e.g., Xalatan® 50 µg/mL, Pfizer), travoprost, tafluprost, bimatoprost, or unoprostone.
Intraocular pressure (IOP), measured using a Goldmann applanation tonometer, an iCare tonometer, or similar. Change in IOP value (mmHg).
Change in IOP value (mmHg).
Time frame: 6 months
Visual field (VF) - Mean Deviation, measured by automated perimetry testing devices, such as Haag-Streit Octopus, Zeiss Humphrey, or similar
Evaluation of Change in Mean Deviation (MD, dB).
Time frame: 6 months
Visual Field - Pattern Standard Deviation, measured by automated perimetry testing devices, such as Haag-Streit Octopus, Zeiss Humphrey, or similar.
Evaluation of Pattern Standard Deviation (PSD, dB).
Time frame: 6 months
Visual Field - Glaucoma Progression Analysis (GPA), measured by automated perimetry testing devices, such as Haag-Streit Octopus, Zeiss Humphrey, or similar.
Evaluation of Glaucoma Progression Analysis (GPA, %/year).
Time frame: 6 months
Optical Coherence Tomography - Change in Average GCL+IPL Thickness, measured by Heidelberg Spectralis, Zeiss Cirrus, or similar.
Evaluation of Change in Average GCL+IPL thickness (µm).
Time frame: 6 months
Optical Coherence Tomography - Average RNFL Thickness, measured by Heidelberg Spectralis, Zeiss Cirrus, or similar.
Evaluation of average RNFL thickness (µm).
Time frame: 6 months
Optical Coherence Tomography - Disc Rim Area, measured by Heidelberg Spectralis, Zeiss Cirrus, or similar.
Evaluation of Disc Rim Area (mm²).
Time frame: 6 months
Optical Coherence Tomography - Cup-to-disc Ratio, measured by Heidelberg Spectralis, Zeiss Cirrus, or similar.
Evaluation of Cup-to-disc ratio (average and vertical).
Time frame: 6 months
Optical Coherence Tomography - Central Subfield Thickness, measured by Heidelberg Spectralis, Zeiss Cirrus, or similar.
Evaluation of Central Subfield Thickness (µm).
Time frame: 6 months
10 Visual Acuity, measured by Best Corrected Visual Acuity (BCVA) score, using Snellen and/or LogMar charts.
Changes in Best Corrected Visual Acuity (BCVA), Snellen and/or LogMar.
Time frame: 6 months
Adverse Events, as reported in patient's medical history.
Reported blurred vision, conjunctival hyperemia, dryness, itching, irritation, pain, light sensitivity, eye lash growth, changes in iris colour, orbital fat atrophy/periorbitopathy, intraocular inflammation, macular oedema, vitreous floaters.
Time frame: 6 months
Adherence to Study Treatment
Evaluation of number and percentage of participants adherence/compliance to study treatment (Yes or No).
Time frame: 6 months
Additional Glaucoma Interventions
Evaluation of number and percentage of occurrence of additional glaucoma-related procedures during the follow-up period \[Laser trabeculoplasty and/or cataract surgery\].
Time frame: 6 months
Retinal Cells apoptosis Detected by DARC Imaging
Detection of Apoptosing Retinal Cells Cell Count
Time frame: 6 months
Vascular Outcomes - Change in the FAZ area (OCT-A parameter), measured by Zeiss Cirrus AngioPlex, or similar.
Detection and quantification of Apoptosing Retinal Cells Cell Count (e.g., cells/mm²)
Time frame: 6 months
Vascular outcomes - Change in Peripapillary Vessel Density (OCT-A parameter), measured by Zeiss Cirrus AngioPlex, or similar.
Evaluation of Peripapillary Vessel Density (%).
Time frame: 6 months
Vascular outcomes - Change in Macular Vessel Density (OCT-A parameter), measured by Zeiss Cirrus AngioPlex, or similar
Evaluation of Macular Vessel Density (mm-1).
Time frame: 6 months
Vascular outcomes - Change in perfusion density (OCT-A parameter), measured by Zeiss Cirrus AngioPlex, or similar.
Evaluation of perfusion density (a.u.).
Time frame: 6 months
Start is estimated for May 2026; primary completion for Jun 2026, 1 month later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Association for Innovation and Biomedical Research on Light and Image